DPP4 Inhibitors Confer Increased Odds of Bullous Pemphigoid Even Years After Drug Initiation in Patients With Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation
Arch Dermatol Res 2023 Jan 01;315(1)33-39, K Kridin, O Avni, G Damiani, D Tzur Bitan, E Onn, O Weinstein, AD CohenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.